C-LM4PNeuroBio
T14 peptide, biomarker diagnostics, neurodegeneration therapeutics
modulatingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-LM4P
C-LM4PC-LM4PT14 peptide, biomarker diagnostics, neurodegeneration therapeutics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
NeuroBio T14 peptide, biomarker diagnostics, neurodegeneration therapeutics
Neuro-Bio is a privately owned biotech focused on neurodegenerative diseases, especially Alzheimer's disease. The company has discovered T14, a novel molecule described as toxic in the adult brain and a key driver of neurodegeneration. It is developing a pre-symptomatic biomarker, diagnostic approaches, and drug candidates based on this mechanism.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
NeuroBio — Early mechanism · Bottom quartile. Derived deterministically from 7 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (3 programs at preclinical).…
Source: Deterministic